Easter Sale – 70% Off TipRanks
Sigma Healthcare Ltd ( (AU:SIG) ) has shared an announcement.
Sigma Healthcare, now reporting as a merged group with Chemist Warehouse, has aligned its financial year with Chemist Warehouse’s 30 June year-end following ASIC relief and corresponding ASX confirmations. The reverse acquisition accounting means prior-period comparatives reflect Chemist Warehouse only, reshaping how investors interpret the group’s historical performance and scale.
For the half year to 31 December 2025, the merged group posted sales of $5.51 billion, up 180.5% on the prior corresponding period, and net profit after tax of $379.1 million, an increase of 23.1%. Despite stronger earnings, net tangible asset backing per share fell sharply to 9.0 cents, while the board declared a fully franked interim dividend of 2.0 cents per share for the year ending 30 June 2026, signalling an ongoing commitment to shareholder returns.
The group reported no gains or losses of control over material entities during the period and has no dividend reinvestment plan in place. The reviewed half-year accounts, signed off without modification by PwC, provide the first comprehensive snapshot of the combined Sigma–Chemist Warehouse business and will serve as the baseline for future market disclosures.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
More about Sigma Healthcare Ltd
Sigma Healthcare is an Australian healthcare and pharmacy wholesaler that now includes the Chemist Warehouse retail network after a February 2025 merger. The merged group operates across pharmaceutical distribution and retail pharmacy, with reporting aligned to Chemist Warehouse’s 30 June financial year to streamline compliance and reflect its enlarged retail-focused operations.
Average Trading Volume: 13,911,154
Technical Sentiment Signal: Buy
Current Market Cap: A$34.45B
See more data about SIG stock on TipRanks’ Stock Analysis page.
Leave a comment